Key Documents

View All Documentation

AR-A014418

Name: AR-A014418
Brand: SIGMA

≥98% (HPLC), solid

Synonym(s):

N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₁₂H₁₂N₄O₄S

CAS Number:

487021-52-3

Molecular Weight:

308.31

NACRES:

NA.77

PubChem Substance ID:

329770820

UNSPSC Code:

12352200

MDL number:

MFCD08277040

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

off-white to tan

solubility

DMSO: ≥20 mg/mL, clear, light yellow, H₂O: insoluble

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1

InChI

1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)

InChI key

YAEMHJKFIIIULI-UHFFFAOYSA-N

Description

General description

AR-A014418 may have chronic pain-relieving properties. In mice having neuropathic pain, this molecule has been shown to have antihyperalgesic effects. AR-A014418 may modulate proinflammatory cytokines and the catecholaminergic and serotonergic pathways. It has also been studied that AR-A014418 inhibits growth of pancreatic cancer cells.

Application

AR-A014418 has been used as an inhibitor of glycogen synthase kinase 3 (GSK3).

Biochem/physiol Actions

AR-A014418 is a glycogen synthase kinase 3 (GSK3) inhibitor.

Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer′s disease. GSK3 inhibitor, AR-A014418, inhibits GSK3 (IC₅₀ = 104 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC₅₀> 100 μM) or 26 other kinases, demonstrating high specificity for GSK3.

Features and Benefits

This compound is featured on the PKB/Akt page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	G5547	D1944	SML0360
Sigma-Aldrich A3230 AR-A014418	Sigma-Aldrich G5547 GSK837149A	Sigma-Aldrich D1944 D4476	Sigma-Aldrich SML0360 TAK-715
form solid	form solid	form solid	form powder
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: ≥20 mg/mL, clear, light yellow, H₂O: insoluble	solubility DMSO: >10 mg/mL, H₂O: insoluble	solubility DMSO: ~20 mg/mL, H₂O: insoluble	solubility DMSO: >15 mg/mL
color off-white to tan	color white to off-white	color light yellow	color faintly yellow to dark yellow

Storage Class

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

GSK3beta inhibition promotes synaptogenesis in Drosophila and mammalian neurons

Cuesto G, et al.

PLoS ONE, 10(3), e0118475-e0118475 (2015)

Glycogen synthase kinase 3β inhibition prevents monocyte migration across brain endothelial cells via Rac1-GTPase suppression and down-regulation of active integrin conformation.

Slava Rom et al.

The American journal of pathology, 181(4), 1414-1425 (2012-08-07)

Glycogen synthase kinase (GSK) 3β has been identified as a regulator of immune responses. We demonstrated previously that GSK3β inhibition in human brain microvascular endothelial cells (BMVECs) reduced monocyte adhesion/migration across BMVEC monolayers. Herein, we tested the idea that GSK3β

Signalling through the type 1 insulin-like growth factor receptor (IGF1R) interacts with canonical Wnt signalling to promote neural proliferation in developing brain.

Qichen Hu et al.

ASN neuro, 4(5) (2012-05-26)

Signalling through the IGF1R [type 1 IGF (insulin-like growth factor) receptor] and canonical Wnt signalling are two signalling pathways that play critical roles in regulating neural cell generation and growth. To determine whether the signalling through the IGF1R can interact

View All Related Papers

Global Trade Item Number

SKU	GTIN
A3230-5MG	04061832433783
A3230-25MG	04061832433776

Questions

Reviews

No rating value